Characterization of Alternative Splicing in High-Risk Wilms' Tumors.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
20 Apr 2024
Historique:
received: 22 02 2024
revised: 05 04 2024
accepted: 15 04 2024
medline: 27 4 2024
pubmed: 27 4 2024
entrez: 27 4 2024
Statut: epublish

Résumé

The significant heterogeneity of Wilms' tumors between different patients is thought to arise from genetic and epigenetic distortions that occur during various stages of fetal kidney development in a way that is poorly understood. To address this, we characterized the heterogeneity of alternative mRNA splicing in Wilms' tumors using a publicly available RNAseq dataset of high-risk Wilms' tumors and normal kidney samples. Through Pareto task inference and cell deconvolution, we found that the tumors and normal kidney samples are organized according to progressive stages of kidney development within a triangle-shaped region in latent space, whose vertices, or "archetypes", resemble the cap mesenchyme, the nephrogenic stroma, and epithelial tubular structures of the fetal kidney. We identified a set of genes that are alternatively spliced between tumors located in different regions of latent space and found that many of these genes are associated with the epithelial-to-mesenchymal transition (EMT) and muscle development. Using motif enrichment analysis, we identified putative splicing regulators, some of which are associated with kidney development. Our findings provide new insights into the etiology of Wilms' tumors and suggest that specific splicing mechanisms in early stages of development may contribute to tumor development in different patients.

Identifiants

pubmed: 38674106
pii: ijms25084520
doi: 10.3390/ijms25084520
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Israel Science Foundation
ID : ICORE no. 1902/12 and Grants no. 1634/13, 2017/13, and 1814/20
Organisme : Israel Ministry of Health
ID : Grant no. 3-10146
Organisme : EU-FP7
ID : Marie Curie International Reintegration Grant no. 618592
Organisme : Data Science Institute at Bar-Ilan University
ID : seed grant
Organisme : Israel Cancer Research Fund
ID : Grant no. 19-101-PG
Organisme : Israel Ministry of Science
ID : Grant no. 3-16220
Organisme : Israel Cancer Association
ID : Grant no. 20240114

Auteurs

Yaron Trink (Y)

Faculty of Engineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, Ramat Gan 5290002, Israel.

Achia Urbach (A)

The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan 5290002, Israel.

Benjamin Dekel (B)

Pediatric Stem Cell Research Institute and Division of Pediatric Nephrology, Edmond and Lily Safra Children's Hospital, Sheba Tel-HaShomer Medical Centre, Ramat Gan 5262000, Israel.

Peter Hohenstein (P)

Department of Human Genetics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Jacob Goldberger (J)

Faculty of Engineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, Ramat Gan 5290002, Israel.

Tomer Kalisky (T)

Faculty of Engineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, Ramat Gan 5290002, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH